Impact of the therapy by renin–angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension
Authors:
- 28 February 2008
- journal article
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 22 (5) , 338-345
Abstract
The aim of the study was to investigate the effect of therapy by perindopril or telmisartan on endothelial/platelet function and on coagulation/fibrinolysis in 20 and 16 hypertensive patients, respectively. The measurements were carried out before and after 1 month of therapy. Both systolic blood pressure and diastolic blood pressure were reduced (Pin vivo platelet activation, plasminogen activator inhibitor type 1 (PAI-1) antigen and tissue type plasminogen activator (tPA) antigen as markers of fibrinolytic activity, soluble endothelial protein C receptor (sEPCR) as a new marker of hypercoagulation and fibrinogen level as a known risk factor for vascular changes were investigated. A decrease of plasma vWF, sPsel, sGpV, PAI-1 and tPA antigen level (PP<0.05, respectively) after 1 month of therapy by telmisartan was found. We failed to find changes of plasma TM, βTG and PF4 due to any therapy investigated. The additional beneficial ‘antithrombotic’ effects of the renin–angiotensin system targeting agents (vasculoprotective, anti-platelet and profibrinolytic effects of perindopril and anticoagulant/rheological effects of telmisartan) may be important in terms of the favourable role of antihypertensive drugs in cardiovascular morbidity.Keywords
This publication has 44 references indexed in Scilit:
- Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blockerJournal Of Hypertension, 2007
- Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy‐resistant hypertensive patientsJournal of Thrombosis and Haemostasis, 2007
- TelmisartanDrugs, 2006
- Soluble Platelet Glycoprotein V Is a Marker of Thrombosis in Patients With Ischemic StrokeStroke, 2005
- Relationship of homocysteine to markers of platelet and endothelial activation in ‘high risk’ hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes TrialInternational Journal of Cardiology, 2004
- A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosisBlood, 2004
- Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapyAnnals of Medicine, 2004
- Different Effect of Antihypertensive Drugs on Conduit Artery Endothelial FunctionHypertension, 2003
- Effects of Antihypertensive Drugs on Endothelial DysfunctionDrugs, 2002
- Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet functions in essential hypertensionPlatelets, 1998